# Eli Lilly and Co. shares were little changed in Monday's premarket session.

*biotech · news · 2026-04-13 · Benzinga*

## Key points

- Eli Lilly's Jaypirca combined with venetoclax and rituximab significantly improved progression-free survival in CLL/SLL.
- The BRUIN CLL-322 trial marks Jaypirca's fourth positive Phase 3 study, supporting potential label expansion this year.
- Jaypirca showed non-inferiority and numerically higher response rates versus Imbruvica in the BRUIN CLL-314 trial.
- Retevmo's Phase 3 LIBRETTO-432 trial showed significant event-free survival improvement in early-stage lung cancer patients.

**Companies:** Eli Lilly and Co., AbbVie Inc., Johnson & Johnson
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/markets/biotech/26/04/51778598/eli-lillys-jaypirca-builds-case-with-fourth-positive-phase-3-trial-in-blood-cancer-patients)

---

Canonical: https://newsio.io/n/c5c3ae3a-18a3-4bec-a3ec-79f12a62b197/eli-lilly-and-co-shares-were-little-changed-in-mondays-premarket-session-the-u-s
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works